News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Deals
Bristol-Myers Squibb Company Announces Expiration of Hart-Scott-Rodino Review Period for Acquisition of Medarex, Inc.
August 12, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that the Hart-Scott-Rodino (HSR) review period for its tender offer for Medarex, Inc. (NASDAQ: MEDX) has expired.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Bristol Myers Squibb Company
MORE ON THIS TOPIC
Deals
An Insmed takeout by Sanofi would be ‘clear strategic fit’ in respiratory space
November 20, 2026
·
2 min read
·
Heather McKenzie
Cancer
Merck-Kelun ADC scores survival win in Phase 3 gastroesophageal cancer trial
November 20, 2026
·
3 min read
·
Gabrielle Masson
Earnings
Novartis projects slowed growth, pins hopes on billions in pipeline potential
November 19, 2026
·
3 min read
·
Annalee Armstrong
Licensing
AbbVie grooves with DISCO’s solid tumor tech in up to $2.5B licensing deal
November 19, 2026
·
1 min read
·
Annalee Armstrong